The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma

Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors

(2018) Paola Orlandi et al.   BIOCHEMICAL PHARMACOLOGY

Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Blood. 2017;130(16):1800-1808.

(2018)   BLOOD

Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma

(2018) Stefania Orecchioni et al.   BRITISH JOURNAL OF CANCER

Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data

(2018) Gianfranco Natale et al.   CANCER LETTERS

Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi

(2018) Sergio Storti et al.   HAEMATOLOGICA

Metronomic combination of vinorelbine and 5Fluorouracil inhibit triple-negative breast cancer cells results from the proof-of-concept VICTOR-0 study

(2018) Maria Grazia Cerrito et al.   Oncotarget

Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi

(2018) Sergio Storti et al.   HAEMATOLOGICA

Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial

(2018) Qiu-Dan Shen et al.   Lancet Haematology

Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients

(2018) Abhijeet Kumar et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience

(2018) Roland Christian Schelker et al.   BMC CANCER

A retrospective multicentre study of COCKLE, an oral chemotherapy regimen, as palliative treatment for high grade lymphoma

(2018) Bernard Maybury et al.   BRITISH JOURNAL OF HAEMATOLOGY

Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma

(2018) Hanno M. Witte et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

(2018) Roch Houot et al.   LEUKEMIA

Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi

(2017) Stefano Luminari et al.   HEMATOLOGICAL ONCOLOGY

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

(2017) Frédéric Peyrade et al.   Lancet Haematology

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin’s lymphoma

(2016) Jiangzheng Zeng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab

(2016) P. L. Zinzani et al.   HAEMATOLOGICA

Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients

(2016) Teresa Di Desidero et al.   INVESTIGATIONAL NEW DRUGS

Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect

(2016) Guido Bocci et al.   Nature Reviews Clinical Oncology

Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab

(2016) P. L. Zinzani et al.   HAEMATOLOGICA

Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients withde novodiffuse large B cell lymphoma

(2015) Toby A. Eyre et al.   BRITISH JOURNAL OF HAEMATOLOGY

Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition

(2015) L. MAVROEIDIS et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria

(2015) Armin Rashidi et al.   LEUKEMIA & LYMPHOMA

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study

(2015) Annalisa Arcari et al.   LEUKEMIA & LYMPHOMA

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)

(2014) Alessandra Tucci et al.   LEUKEMIA & LYMPHOMA

Clinicopathologic Characterization of Diffuse-Large-B-Cell Lymphoma with an Associated Serum Monoclonal IgM Component

(2014) M. Christina Cox et al.   PLoS One

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

(2013) Evangelos Briasoulis et al.   BMC CANCER

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2013) Ken Ohmachi et al.   JOURNAL OF CLINICAL ONCOLOGY

De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial

(2013) Paul A. Fields et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi

(2013) Francesco Merli et al.   LEUKEMIA & LYMPHOMA

Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma – A report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE)

(2012) Véronique Minard-Colin et al.   EUROPEAN JOURNAL OF CANCER

Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell Lymphoma

(2012) M. Spina et al.   ONCOLOGIST

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

(2011) Frédéric Peyrade et al.   LANCET ONCOLOGY

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

(2009) Gaetano Corazzelli et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: Low-dose metronomic, multidrug therapy

(2008) Morton Coleman et al.   CANCER